Launceston General Hospital

The trials here

What the 15 trials at this site are about, from their registry records.

Conditions

• Gastric and oesophageal cancer3 trials
• Lung cancer3 trials
• Childhood cancers2 trials
• Stroke2 trials
• Type 2 diabetes2 trials
• ALS (motor neurone disease)1 trial
• Heart failure1 trial
• Huntington's disease1 trial
• Mesothelioma1 trial
• Multiple myeloma1 trial
• Ovarian cancer1 trial
• Type 1 diabetes1 trial

Phase

• Phase 38 trials
• Phase 2/32 trials
• Phase 21 trial

Status

• Completed5 trials
• Active, not recruiting4 trials
• Recruiting3 trials
• Not yet recruiting2 trials
• Terminated1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• Launceston General Hospital2 trials
• Australasian Gastro-Intestinal Trials Group1 trial
• Australian and New Zealand Intensive Care Research Centre1 trial
• Bayer1 trial
• and 8 more

Running trials

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Eli Lilly and Company· Source

  Contact: Jeremy Power (principal investigator)

• Active, not recruiting

  Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

  NCT06873334· Phase 2/3· Skyhawk Therapeutics, Inc.· Source

• Recruiting

  Implementing Surgery School Prehabilitation Using Telehealth

  NCT06631872· University of Melbourne· Source

  Contact: Ianthe Boden, PhD

• Not yet recruiting

  Textbook Outcomes After Oesophagectomy in Regional Australia

  NCT06721715· Launceston General Hospital· Source

  Contact: Girish Pande, FRACS

• Not yet recruiting

  Post Oesophagectomy Outcomes in a Single Regional Centre in Australia

  NCT06662513· Launceston General Hospital· Source

  Contact: Girish Pande, FRACS

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  The EXCEL Registry of Patients Requiring ECMO

  NCT03793257· Australian and New Zealand Intensive Care Research Centre· Source

  Contact: Matthew Brain, MD (principal investigator)

• Active, not recruiting

  Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma

  NCT01924819· Phase 2/3· Australasian Gastro-Intestinal Trials Group· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Heart failure1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Terminated

  RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial

  NCT06658977· Phase 3· Macquarie University, Australia· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

  NCT05352815· Phase 3· Novo Nordisk A/S· Source

• Completed

  Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

  NCT05014815· Phase 2· BeiGene· Source

• Completed

  DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

  NCT04334759· Phase 3· PrECOG, LLC.· Source

• Completed

  A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

  NCT04255433· Phase 3· Eli Lilly and Company· Source